Almatica Pharma
Focus: Almatica Pharma is a newly-public (2024) specialty pharmaceutical company focused on small-molecule drugs across neurology, infectious diseases, cardiovascular, and psychiatry. The company operates a legacy portfolio of established products with significant revenue concentration in GRALISE (53% of revenue).
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
8-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at Almatica Pharma?
AI assessmentAlmatica is a turnaround/asset management play suitable for professionals seeking stability and operational execution roles, not innovation-driven career growth.
Why Work Here
- Recently went public (2024) with established revenue base ($42M+ in Part D spending across portfolio), offering more stability than early-stage biotech.
- 100% H1B approval rate (3/3 in 2023) signals openness to international talent and visa sponsorship.
Data completeness
5/9 — Partial
Company HealthWatch
Pipeline
Early-stage
0 total
LOE Risk
1 imminent
VENLAFAXINE BESYLATE
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$23M Part DDeclining
LOE Approaching
Flagship product generating 53% of company revenue but facing imminent generic competition; primary revenue cliff risk.
Help build intelligence for Almatica Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.